Considerations for Including Tissue Biopsies in Clinical Trials
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
January 7, 2025
June 4, 2025
857b6b17-0402-45c3-8095-dcd482a60269
Related Documents
Clinical Pharmacology Considerations for Peptide Drug Products
Guidance DocumentDecember 14, 2023Center for Drug Evaluation and Research
Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations
Guidance DocumentMarch 18, 2014Center for Drug Evaluation and Research
Research Involving Children as Subjects and Not Otherwise Approvable by an Institutional Review Board: Process for Referrals to Food and Drug Administration and Office for Human Research Protections: Draft Guidance for Institutional Review Boards, Investigators, and Sponsors
Guidance DocumentMarch 30, 2023Office of the Commissioner
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.